Inhibitex to Present at the 23rd Annual JPMorgan Healthcare Conference
ATLANTA, GA -- 01/04/2005 -- Inhibitex, Inc. (NASDAQ: INHX) announced today that it will present at the 23rd Annual JPMorgan Healthcare Conference on Thursday, January 13, 2005 at 12:00 p.m. PST (3:00 p.m. EST) from the Westin St. Francis, in San Francisco. Inhibitex senior management will provide an update on the company’s late stage clinical programs for Veronate and Aurexis.
The live audio webcast of the presentation will be available at www.inhibitex.com on the Investors section of the Company’s website under the Upcoming Events category. This webcast will be archived and available on the Inhibitex website after the event for a period of 30 days.
Inhibitex, Inc., headquartered in Alpharetta, Georgia, is a biopharmaceutical company focused on the discovery, development and commercialization of antibody-based products for the prevention and treatment of serious, life-threatening infections. The Company currently has five drug development programs, all of which are based on its proprietary MSCRAMM protein platform technology. The Company’s most advanced product candidates are Veronate and Aurexis, both of which the Company has retained all world-wide rights to. Both Veronate and Aurexis have been granted Fast Track designation by the FDA. The Company’s preclinical programs include a collaboration and joint development agreement with Dyax to develop fully human monoclonal antibodies against MSCRAMM proteins on enterococci and a partnership with Wyeth to develop staphylococcal vaccines.
Inhibitex®, MSCRAMM®, Veronate® and Aurexis® are registered trademarks of Inhibitex, Inc.
- Contact Information
- Russell H. Plumb
- Chief Financial Officer
- Inhibitex, Inc.
- Contact via E-mail
This news content was configured by WebWire editorial staff. Linking is permitted.
News Release Distribution and Press Release Distribution Services Provided by WebWire.